Cancer screening cadence
A handful of cancer screening tests genuinely save lives in the people they were designed for. Several others mostly find cancers that would never have caused harm — so the useful question is not how much screening you do, but which tests, and when.
Do the short list and finish it: bowel screening from 45, a mammogram every two years from 40 to 74, an HPV test every five years from 30 to 65, a yearly low-dose lung CT if you are a heavy current or recent smoker aged 50 to 80, and one-time checks for hepatitis C and (for men 65–75 who have ever smoked) an aortic aneurysm. Talk through a PSA test rather than ordering it by reflex, and skip whole-body scans, routine skin checks and multi-cancer blood tests.
Screening saves cancer deaths, not much lifespan
A test can prevent death from one cancer without measurably lengthening the average life of the people screened. A pooled analysis of 18 randomized trials in 2.1 million people worked out how much life each common test buys when averaged across everyone screened.[1]
| Test | Average lifetime gained per person screened | Range compatible with the data |
|---|---|---|
| Sigmoidoscopy | 110 days | 0 to 274 days |
| Low-dose lung CT | 107 days | 286 days lost to 430 gained |
| PSA (prostate) | 37 days | 37 lost to 73 gained |
| Colonoscopy | 37 days | 146 lost to 146 gained |
| Mammography (every two years, 50–69) | 0 days | 190 lost to 237 gained |
| Stool blood test | 0 days | 71 lost to 71 gained |
The third column is the range where the true effect most plausibly lies. Every row but the first includes the possibility of losing time, and the first stops exactly at zero: the trials are compatible with these tests buying nothing.
An average of zero still hides real winners — the woman whose small tumor was caught early gains years; the many women who never get breast cancer gain nothing. But it argues for a few high-value tests done well, not a long list done because the tests exist.
The worry that screening kills people indirectly — false-alarm cascades, radiation, needless procedures — was tested across 17 randomized trials in 1.3 million people. Deaths from non-cancer causes rose by 0.2% in the screened groups, a difference indistinguishable from zero, and the data rule out any increase larger than about 1%.[2]
Bowel cancer: start at 45, and pick the test you will actually do
The US Preventive Services Task Force (the main US screening panel) lowered the starting age from 50 to 45 in 2021, after colorectal cancer in 40–49-year-olds rose by nearly 15% over about fifteen years. It recommends screening firmly from 50 to 75, a little less firmly from 45 to 49, and case by case from 76 to 85.[3] Cases in under-50s are still climbing, by 3% a year in adults aged 20 to 49 across 2013–2022.[4]
The first large randomized trial of screening colonoscopy itself, NordICC, followed about 85,000 healthy 55–64-year-olds in Poland, Norway and Sweden, one invited to a colonoscopy for every two left alone.[5] After 13 years, being invited cut colorectal cancer cases by about a fifth — 1.46% against 1.80%. Deaths from it moved much less, 0.41% against 0.47%, a difference compatible with no effect.[6] Only 42% of those invited turned up, the benefit was clear in men but not in women, and the trial had too few deaths to answer its death question. Deaths from any cause were the same in both groups, 11.03% against 11.04% at ten years.[7] Colonoscopy prevents bowel cancer when it is done; its effect on dying of it remains unproven.
The test you will complete beats the test you keep putting off. A Spanish trial randomized 57,404 adults aged 50 to 69 to one colonoscopy or a stool test every two years; after 10 years colorectal cancer deaths were 0.22% against 0.24%, which met the trial's test for the stool test being no worse.[8] More people did the stool test than showed up for the colonoscopy — 39.9% against 31.8%. In a later analysis of those who actually started screening — not itself randomized — cancer rates and deaths from any cause were statistically indistinguishable either way.[9]
Breast cancer: every two years from 40
The Task Force moved the starting age for mammography from 50 to 40 in 2024, every two years through 74.[10] Starting at 40 rather than 50 is estimated to prevent about 1.3 extra breast cancer deaths per 1,000 women over a lifetime, and about 1.8 per 1,000 Black women.[11] Black women's breast cancer death rate is about 40% higher than White women's.[12]
Two situations still have insufficient evidence either way: screening beyond 75, where other causes of death start to dominate, and extra imaging for dense breasts (more than 40% of screened women). In women with dense breasts and a normal mammogram, abbreviated MRI and contrast-enhanced mammography each found roughly 17 to 19 extra cancers per 1,000 scans, against about 4 for automated ultrasound. Contrast mammography carried the one real harm signal — occasional reactions to the iodine dye.[13] No trial has shown that any of this means fewer deaths.
"Stage 0" breast cancer: surgery is not automatic
Ductal carcinoma in situ (DCIS) — abnormal cells confined to the milk ducts — makes up about 18% of new US breast cancer diagnoses, almost all found by screening.[14] A model of screening every two years from age 50 estimates that roughly 1 in 5 DCIS cases in a screened population is overdiagnosis.[15] The usual response has nonetheless been immediate surgery.
In an observational study of 1,780 US women whose DCIS was not operated on within six months, invasive cancer appeared in the same breast in 8.5% of the low-risk group and 13.9% of the high-risk group over eight years.[16] A randomized trial then tested it directly. In nearly 1,000 women with low-risk, hormone-sensitive DCIS, monitoring every six months was no worse than surgery after two years: invasive cancer appeared in 4.2% of the monitored group and 5.9% of the operated group, and quality of life was much the same.[17], [18] Two years is short for a disease measured in decades, but low-risk DCIS did not punish the women who waited.
Cervical cancer: an HPV test every five years
Testing for high-risk strains of human papillomavirus (HPV) finds 40% more serious precancerous lesions and 30% more cancers per round than the older smear test.[19] After a negative HPV test, the odds of such a lesion by the next round are about four times lower than after a negative smear, which is why the interval can stretch to five years for HPV-negative women.[20]
Two exceptions shorten it. A self-collected sample means three years, not five. The American Cancer Society now accepts a self-collected vaginal sample for average-risk people aged 25 to 65, but recommends repeating it after 3 years.[21] And clearing an HPV infection does not reset the clock. Women who test positive and then negative carry about three times the later risk of a serious lesion, so that first negative test buys three years, not five.[22]
Prostate cancer: a conversation, not a reflex
After 23 years and 162,236 men, the largest European trial shows 13% fewer prostate cancer deaths with PSA screening. In absolute terms that is about 2 fewer deaths per 1,000 men invited: about 456 men must be invited and 12 diagnosed and treated to prevent one death, both figures uncertain. Screened men were diagnosed with prostate cancer 30% more often.[23] A US trial that found no benefit is largely explained by many of its "unscreened" men getting PSA tests anyway.[24]
So PSA works, but testing every man generates a lot of overtreatment — incontinence, erectile dysfunction, and the heart side effects of hormone-blocking therapy — for a small gain. The better pathway starts from a baseline PSA, spaces tests out when it is low, uses MRI before any biopsy, and watches low-grade cancer rather than removing it. A preliminary report from one screening round of a Finnish trial — PSA, then a blood-marker panel, then MRI before any biopsy — found about 4.6 extra aggressive cancers for every extra low-grade one.[25] The UK's first prostate programme, recommended in 2026, is limited to men aged 45–61 with a disease-causing BRCA2 gene variant and a family history; screening all men was explicitly declined.
Lung cancer: yearly low-dose CT for heavy smokers
The Task Force recommends a yearly low-dose CT scan for adults 50–80 with at least 20 pack-years of smoking (a pack a day for 20 years, or the equivalent) who still smoke or quit within the last 15 years. Screening stops after 15 years off cigarettes, or once a health problem substantially limits life expectancy or the ability or willingness to have curative lung surgery.[26]
That 15-year cutoff is contested. The American Cancer Society drops it entirely,[27] because risk keeps rising after 15 quit-years by roughly 9% a year as age outruns the benefit of having stopped.[28] US insurance follows the Task Force, so someone who quit 18 years ago after 40 pack-years is eligible on one reading and unfunded on the other.
In the large US trial, three yearly scans cut lung cancer deaths by 20% — but compared with chest X-rays, not with no screening.[29] A Dutch–Belgian trial that did compare against no screening found about 24% fewer lung cancer deaths in men at ten years; too few women took part to settle it for them.[30]
The cost is false alarms: harmless scars and nodules light up the same way, leading to repeat scans, bronchoscopy and biopsies of benign tissue. Within the US trial, screening cost about $81,000 per year of healthy life gained, with a plausible range of $52,000 to $186,000, and its authors warned that modest changes in assumptions would greatly alter the figure.[31]
Hepatitis C and aortic aneurysm: one test each, in the right people
Both are simple one-off tests with solid evidence behind them in the groups they target.
Hepatitis C, once for most adults 18–79. Modern antiviral pills clear the virus in 95% to 99% of people who take them,[32] so the Task Force now recommends a one-time antibody test for everyone 18 to 79, followed automatically by a test for the virus's genetic material if positive, with repeat testing for anyone still at risk.[33]
Abdominal aortic aneurysm: one ultrasound, for men 65–75 who have ever smoked. That is where the survival benefit concentrates. European vascular guidelines add that pre-surgical imaging and planning should wait until the bulge reaches about 55 mm in men or 50 mm in women, and that repair should be done at centres performing at least 15 open and 15 catheter-based (endovascular) repairs a year.[34]
Skin checks: not as a routine
The Task Force finds insufficient evidence for routine doctor-performed skin checks in people without symptoms.[35] Its review covered 20 studies and over 6 million people, but the evidence on deaths came from three non-randomized analyses of two German programmes. Germany has offered free skin checks every two years to every adult 35 and over since 2008, and melanoma deaths there fell no faster than in nine neighbouring countries with no screening — a population-level comparison, not a trial.[36] Routine checks find many early melanomas, much of which appear slow-growing — each meaning surgery and worry — without proportionally reducing the fast-growing ones that kill.
None of this argues against seeing a doctor for a suspicious mole, or against a dermatologist's care if you have a family history, very fair skin that burns, or many atypical moles.
Overdiagnosis: the thyroid lesson
Overdiagnosis is a by-product of screening, not a malfunction. Thyroid cancer shows it most clearly: diagnoses have surged for three decades while deaths stayed flat. A modelling study estimates that 72% to 94% of US papillary thyroid cancer diagnoses between 1991 and 2019 were overdiagnoses — roughly 550,000 to 730,000 people, many of whom had their thyroid removed, sometimes followed by radioactive iodine, and now take hormone replacement for life.[37] The 2025 American Thyroid Association guidelines allow watching selected low-risk thyroid cancers instead, though as a conditional recommendation on low-certainty evidence.[38] See Thyroid management.
| Cancer | Estimated overdiagnosis | What it leads to |
|---|---|---|
| Papillary thyroid | 72–94% of detected cases (US 1991–2019) | Thyroid removal; lifelong hormone replacement; risk of lasting calcium problems from parathyroid injury |
| DCIS (breast) | ~20% of DCIS in screened women | Lumpectomy, often with radiation or hormone therapy |
| PSA-detected prostate | 23–42% of screen-detected cases (US modelling of 1985–2000 practice, before MRI-first biopsy and routine active surveillance)[39] | Surgery or radiation; incontinence; erectile dysfunction |
| Stage 0/I melanoma | Indolent share of rising incidence | Surgery to remove it; anxiety |
If you get an early-stage result, active surveillance is an established option for low-grade prostate cancer, a conditional one for selected low-risk thyroid cancer, and for low-risk DCIS a strategy that has passed a two-year trial but is not yet standard.
Multi-cancer blood tests: promising, not ready
About two-thirds of cancer deaths come from cancers with no recommended screening test — 68.6% on the one published estimate, from authors five of whom work or worked for a company selling such a test.[40] Multi-cancer blood tests, Galleri the best known, read tumor DNA in the blood and promise to find dozens of cancers from one draw. A UK review of 36 studies found no completed randomized trial and mostly high risk of bias; Galleri caught between 21% and 66% of cancers across studies.[41]
The first big trial, NHS-Galleri in over 142,000 people aged 50 to 77, was presented at a 2026 cancer conference and is not yet peer-reviewed.[42] It missed its main goal: late-stage (III/IV) cases of 12 pre-specified cancers were no fewer — 706 against 688. It found more early-stage cancers and fewer cancers diagnosed as emergencies, and after three yearly rounds only about 1.2% of those tested were sent for investigation without a cancer being found.[43] Finding earlier-stage cancers without preventing late-stage ones fits detecting slow cancers faster rather than dangerous ones earlier. The UK National Screening Committee says these tests need trial evidence of fewer cancer deaths before population use;[44] the trial's cancer-death analysis is due around 2028.[45]
Screening healthy people also competes for the scanners that people with symptoms are waiting for. In the English regions hosting the trial, the share of urgent referrals for three suspected cancers taking more than 28 days to diagnose rose for about a year while it fell elsewhere.[46]
What to actually do
- Bowel from 45. Colonoscopy every 10 years or a stool test every year are the most used; a stool DNA test every 1 to 3 years and CT colonography every 5 years are equally covered.
- The rest of the short list — mammography, HPV, lung CT, hepatitis C and aortic aneurysm — on the schedules above.
- PSA: decide together with your doctor from around 50 (45 with a family history or African ancestry). If you screen, ask about MRI before a first biopsy — the urology guideline makes that a conditional recommendation, and a strong one only before a repeat biopsy.[47]
- Don't read a "Stage 0" result as a surgery order. Ask whether watching is an option.
- Remember the bigger levers. Not smoking, blood pressure, lipids, sleep, exercise and weight still dominate the longevity arithmetic.
What's overrated
- Whole-body MRI and CT for healthy adults. Marketed aggressively; no randomized evidence of fewer deaths; plenty of false-alarm cascades.
- Neck ultrasound for thyroid nodules you can't feel — the test that produced the thyroid overdiagnosis wave.
- Routine skin checks and multi-cancer blood tests — see above.
Further reading
- Bretthauer M et al. Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials. JAMA Intern Med 2023.[48]
- Bretthauer M et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death (NordICC). N Engl J Med 2022.[49]
- US Preventive Services Task Force. Screening for Breast Cancer: USPSTF Recommendation Statement. JAMA 2024.[50]
- Ryser MD et al. Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study. BMJ 2025.[51]
- Poelhekken K et al. Overdiagnosis of ductal carcinoma in situ by grade and definition in population-based screening: a modeling study. The Breast 2025.[52]
- Rebolj M et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ 2019.[53]
- Roobol MJ et al. European Study of Prostate Cancer Screening — 23-Year Follow-up. N Engl J Med 2025.[54]
- Tsodikov A et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med 2017.[55]
- Henrikson NB et al. Skin Cancer Screening: Updated Evidence Report and Systematic Review for the USPSTF. JAMA 2023.[56]
- Francis DO et al. Overdiagnosis of Papillary Thyroid Cancer. JAMA Netw Open 2026.[57]
- Batson S et al. UK National Screening Committee position statement on evidence required for multicancer detection tests. BMJ 2026.[58]
- NHS-Galleri trial — topline results. GRAIL press release, 2026.[59]